Quantitative Models and Construction Methods Model Name: CSI 500 Index Enhancement Model - **Model Construction Idea**: The model is constructed using a series of continuous financial factors reflecting corporate governance capabilities combined with some technical factors[3][10][43] - **Model Construction Process**: - Monthly rebalancing frequency for the investment portfolio - Backtest data from March 18, 2021, to March 18, 2026 - Use previous year's semi-annual report data for rebalancing from January to April, previous year's annual report data for rebalancing from May to August, and current year's semi-annual report data for rebalancing from September to December - Data cleaning including missing value handling and standardization - Factors used: momentum factor, low volatility factor, low debt factor, operational capability factor, growth factor, profitability factor[3][43] - **Model Evaluation**: The model successfully outperformed the benchmark index, achieving significant excess returns, but there is still room for optimization in factor construction, timing mechanism, and stock selection efficiency[3][49][50] Model Backtest Results - **CSI 500 Index Enhancement Model**: - Cumulative Return: 63.84%[46][48] - Excess Cumulative Return: 34.79%[46][48] - Annualized Return: 10.83%[46][48] - Excess Annualized Return: 5.38%[46][48] - Annualized Volatility: 17.94%[46][48] - Excess Volatility: -2.92%[46][48] - Sharpe Ratio: 0.60[46][48] - Excess Sharpe Ratio: 0.34[46][48] - Maximum Drawdown: 23.86%[46][48] - Excess Maximum Drawdown: -17.95%[46][48] - Daily Win Rate: 53.39%[46][48] - Excess Daily Win Rate: 1.74%[48] Quantitative Factors and Construction Methods Factor Name: Profitability Factor - **Factor Construction Idea**: Reflects the efficiency of using net assets to generate profits and the profit margin of core business[10] - **Factor Construction Process**: - Net Asset Return (ROE): Reflects the efficiency of using net assets to generate profits, a core indicator of shareholder returns - Gross Profit Margin: Reflects the profit margin of core business, an important manifestation of the company's "moat"[10] - **Factor Evaluation**: These factors comprehensively and accurately quantify the quality of corporate governance, providing a solid theoretical and data support for stock selection strategies[10][11] Factor Name: Debt Capacity Factor - **Factor Construction Idea**: Reflects the company's long-term debt level and financial risk, as well as short-term debt capacity and financial liquidity[10] - **Factor Construction Process**: - Asset-Liability Ratio: Reflects the company's long-term debt level and financial risk - Current Ratio: Reflects the company's short-term debt capacity and financial liquidity[10] - **Factor Evaluation**: These factors form the "firewall" of corporate financial security, providing a solid theoretical and data support for stock selection strategies[10][11] Factor Name: Operational Efficiency Factor - **Factor Construction Idea**: Reflects the efficiency of capital recovery and bargaining power, as well as the speed of inventory realization and inventory management level[10] - **Factor Construction Process**: - Accounts Receivable Turnover Ratio: Reflects the efficiency of capital recovery and bargaining power - Inventory Turnover Ratio: Reflects the speed of inventory realization and inventory management level[10] - **Factor Evaluation**: These factors directly reflect the company's operational management efficiency and resource utilization capabilities, providing a solid theoretical and data support for stock selection strategies[10][11] Factor Backtest Results - **Profitability Factor**: - ROE: Reflects the efficiency of using net assets to generate profits[10] - Gross Profit Margin: Reflects the profit margin of core business[10] - **Debt Capacity Factor**: - Asset-Liability Ratio: Reflects the company's long-term debt level and financial risk[10] - Current Ratio: Reflects the company's short-term debt capacity and financial liquidity[10] - **Operational Efficiency Factor**: - Accounts Receivable Turnover Ratio: Reflects the efficiency of capital recovery and bargaining power[10] - Inventory Turnover Ratio: Reflects the speed of inventory realization and inventory management level[10]

Core Viewpoint - Zhaoyan New Drug (06127) experienced a significant stock increase of over 14%, reaching HKD 22.3 with a trading volume of HKD 76.51 million following the release of its annual performance report [1] Financial Performance - In 2025, the company reported an operating revenue of RMB 1.658 billion, a year-on-year decrease of 17.87% [1] - The net profit attributable to shareholders was RMB 298 million, showing a substantial year-on-year increase of 302.08% [1] Order Status - The total amount of orders on hand is approximately RMB 2.6 billion, with new signed orders also amounting to RMB 2.6 billion, both reflecting year-on-year growth [1] Profit Drivers - The increase in net profit is primarily attributed to gains from changes in the fair value of biological assets, which contributed a net income of RMB 476 million during the period [1] - The biological assets mainly consist of non-human primate experimental models used for non-clinical project evaluations, commonly referred to as "experimental monkeys" [1]

Group 1 - The report highlights that Chaoyun Group has maintained high dividends for six consecutive years, with revenue and profit both showing year-on-year growth, indicating a sustainable growth outlook for its product matrix [4][5] - In 2025, Chaoyun Group achieved a revenue of 1.988 billion RMB, a year-on-year increase of 9.24%, and a net profit of 224 million RMB, up 9.98% year-on-year, with a comprehensive gross margin of 52.61% [4][5] - The company’s home care products performed well, with revenue from this segment reaching 1.715 billion RMB, a year-on-year increase of 5.0%, while the pet business saw a significant growth of 74.3% [5][6] Group 2 - Jianmin Group's revenue for 2025 was 3.370 billion RMB, a decrease of 3.85% year-on-year, but the fourth quarter showed a strong recovery with an 82.69% increase in net profit [10][11] - The pharmaceutical industrial segment of Jianmin Group reported a revenue of 2.025 billion RMB, a year-on-year increase of 15.91%, driven by strong sales of prescription and OTC products [11][12] - The company is focusing on brand development and innovation, with key products showing significant sales growth, indicating a strong recovery in its core business [11][12] Group 3 - The report on Yimeng Biotech indicates that the B7H3 ADC drug has shown excellent efficacy in treating metastatic castration-resistant prostate cancer (mCRPC), with promising clinical trial results [13][14] - The drug has received fast track designation from the FDA, highlighting its potential in the market [14][15] - The clinical study included 146 patients, showing a median radiographic progression-free survival of 11.3 months, indicating strong therapeutic potential [15][16] Group 4 - Pop Mart reported a revenue of 37.12 billion RMB in 2025, a year-on-year increase of 184.7%, with adjusted net profit rising by 284.5% [18][19] - The company has seen a significant increase in online sales, which accounted for 44.3% of total revenue, reflecting a shift in consumer purchasing behavior [21][22] - The number of IPs generating over 2 billion RMB in revenue has increased, with the "Star People" IP showing a remarkable growth of 1602% [25][26] Group 5 - CIMC Vehicles reported a revenue of 20.18 billion RMB in 2025, a decrease of 3.9% year-on-year, but with a strong performance in the Chinese market, where semi-trailer sales increased by 15% [28][29] - The company anticipates a recovery in the North American market in 2026, with significant order rebounds indicating a potential turnaround [29][30] - The report emphasizes the company's strategic positioning in the global market, particularly in the southern regions, which are expected to drive future growth [28][29] Group 6 - Power Development reported a revenue of 5.293 billion RMB in 2025, a decrease of 6.4% year-on-year, but maintained a high profit margin despite market challenges [32][33] - The company achieved a high dividend payout ratio of 123%, reflecting its commitment to returning value to shareholders [33][34] - The report outlines ongoing projects that are expected to enhance production capacity significantly in the coming years, indicating strong growth potential [34][35] Group 7 - Bluestar Technology is recognized as a leader in adsorption separation materials, with significant growth driven by innovation and market demand in various sectors [37][38] - The company is positioned to benefit from the growing market for small nucleic acid drugs, with projections indicating substantial growth in this area [38][39] - The report forecasts revenues of 2.733 billion RMB for 2025, with a strong growth trajectory expected in subsequent years [39]

Summary of Conference Call Records Industry Overview - The market focus has shifted downwards, with the Shanghai Composite Index's fluctuation range moving from 4,000-4,200 points to 3,700-3,800 points, indicating that 80% of the shares are currently in a locked state [1][4][7] - The second quarter allocation strategy suggests focusing on "new and old energy + cyclical consumption," with attention on collaborative electricity, power equipment, dividend assets (banks/transportation), and agricultural pharmaceuticals [1][11] Key Market Insights - The market is expected to stabilize around the W bottom or complex bottom by mid to late April, initiating a weekly-level rebound, although the probability of a B-wave rebound is higher than reaching new highs due to liquidity and external shocks [1][10] - The current market adjustment may not be over, with ongoing geopolitical tensions in the Middle East contributing to continued volatility in global capital markets [6][10] Sector Performance - Only the utilities and power equipment sectors have maintained upward momentum, while TMT and non-bank sectors have seen significant declines, reflecting a notable decrease in market risk appetite [1][5][11] - The A-share market has shown structural characteristics, with 9 sectors rising and 22 falling, indicating a defensive market environment [5][11] Support and Resistance Levels - The key support level is identified at 3,755 points (0.382 retracement level), with the core defensive range between 3,700-3,800 points, and significant resistance above 4,040 points [1][9][10] - Approximately 40% of shares are distributed above 4,000 points, and another 40% between 3,800 and 4,000 points, leading to about 80% of shares being locked when the index falls to 3,800 points [7][10] Investment Strategy - The strategy emphasizes timing over stock selection, recommending to buy on dips within the 3,700-3,800 point range and sell near 4,000 points to reduce costs [1][10] - Investors are advised to remain patient during the market bottoming process and consider increasing positions once the market stabilizes in mid-April [10][11] Future Market Trends - The market may experience a second bottoming phase, with the potential for a rebound if it can break through the 3,955 point gap [9][10] - The market's future trajectory will depend on fundamental, policy, and liquidity conditions, particularly the performance of major financial sectors [10][11] Sector Focus for Q2 2026 - Key sectors to watch include coal, pharmaceuticals, new energy, agriculture, transportation, and communication, reflecting a blend of growth and stability in the current market environment [11][12] - The market style is characterized by a combination of large-cap growth and stable sectors, indicating a pursuit of certainty amid volatility [12][13]

Core Viewpoint - The A-share market is experiencing a positive trend in Q1 2026 earnings forecasts, with a significant majority of companies reporting expected profit increases, indicating overall market optimism [1]. Group 1: Earnings Forecasts - As of March 29, 2026, 18 companies have disclosed their Q1 earnings forecasts, with 88.89% expecting profit increases, including 10 companies forecasting substantial growth, 5 slight increases, and 1 company turning a loss into profit [1]. - The sectors showing the highest growth are machinery, pharmaceuticals, and basic chemicals, driven by both volume and price increases [1]. Group 2: Notable Companies - Oukeyi is expected to report a net profit of 180 million to 220 million yuan, representing a year-on-year increase of 2248.9% to 2770.9%, primarily due to the rise in hard alloy tool prices and a low base effect from the previous year [1]. - Fuxiang Pharmaceutical forecasts a net profit of 52 million to 75 million yuan, with a year-on-year growth of 2222.67% to 3250.01%, benefiting from the booming demand in the new energy sector [2]. - Kuncai Technology is projected to achieve a net profit of 60 million to 80 million yuan, marking a year-on-year increase of 151.56% to 235.41%, driven by the recovery in titanium dioxide prices [2]. Group 3: Growth Drivers - Wanbangde is expected to report a net profit of 165 million yuan, reflecting a year-on-year increase of 985.4%, attributed to its strategic shift from generic to innovative drugs and increased R&D investment [3]. - Gude Electric Materials anticipates a revenue growth of 41.41% to 53.89%, with a net profit forecast of 48 million to 51 million yuan, driven by successful expansion into copper-aluminum composite materials [3]. Group 4: Other Notable Performances - Aolaide expects a net profit of 70 million to 85 million yuan, with a year-on-year growth of 175.2% to 234.17%, due to its competitive advantage in evaporator equipment [4]. - Tianshan Aluminum is projected to achieve a net profit of 2.2 billion yuan, a year-on-year increase of 107.92%, benefiting from the capacity release of its green low-carbon aluminum project [4].

Core Viewpoint - The article emphasizes the importance of efficiently filtering and interpreting key announcements in the market to identify investment opportunities, highlighting the role of the "Announcement Selection" service in providing concise and understandable insights [1]. Group 1: Selected Highlights - On March 18, the company announced that its smart electric joints and other products have been used in quadruped robotic dogs, biped humanoid robots, and wheeled robots, leading to a 28% increase in stock price over seven consecutive trading days [2]. - On March 23, the company reported a projected increase of over 22 times in its first-quarter earnings due to the synergy of its three main businesses, resulting in a 35% stock price rise over four days [2]. - On March 23, the company introduced its fifth-generation high-pressure solid lithium iron phosphate cathode material with a density of 2.704 g/cm³, which contributed to a 20.6% stock price increase over four consecutive trading days [2]. - On March 24, the company announced the small-scale shipment of its 800G LPO optical modules, which led to consecutive stock price increases for two days [2]. - On March 25, the company disclosed that it is supplying optical module coupling and wafer testing equipment in bulk to Nvidia, resulting in stock price increases of 4.7% and 5.2% on consecutive days [2]. Group 2: Industry Developments - The company has strategically positioned itself in the commercial aerospace lithium battery sector two years ago and plans to invest 6 billion yuan to establish a 60GWh energy storage (power) battery project [3]. - The company has indirectly supplied CMOS image sensors to multiple robotics brand clients, indicating its involvement in the fields of machine vision, security, and consumer electronics [3]. - The company has developed a new generation of solid-state transformers (SST), which have been successfully prototyped, contributing to advancements in wind power, photovoltaics, energy storage, smart grids, data centers, and computing power [3].

Group 1 - The report highlights that the overseas situation remains a key factor affecting the new stock market, with a low risk appetite suggesting a focus on relatively low-positioned directions [1][12] - The new stock market has shown weak performance over several weeks, with an average decline of approximately 2.6% since 2025, and only about 25.5% of new stocks achieving positive returns [1][28] - The report suggests that potential investment opportunities may arise from high-low rotation in relatively low-positioned stocks, especially if the overseas situation stabilizes [2][12] Group 2 - Specific investment directions include focusing on industries with long-term themes such as AI computing power, commercial aerospace, and energy exports, which have significant growth potential [3][12] - The report also mentions the importance of monitoring sectors like innovative pharmaceuticals and new consumption, which may see periodic interest and can be strategically rotated based on expected catalysts [3][12] Group 3 - Upcoming new stocks include companies like Yuelong Technology, Longyuan Co., and Taijin New Energy, which are expected to be listed soon [4][35] - The average issuance price-earnings ratio for new stocks is reported to be around 21.8X, indicating a stable pricing environment despite the low risk appetite in the market [7][35] - The report emphasizes the need for caution in the short term due to the overall market risk appetite being relatively low, which may affect the performance of newly listed stocks [7][35]

- The report includes multiple quantitative models for A-share market timing, such as the "Volume Model," "Feature Institutional Model," "Feature Volume Model," "Smart Algorithm Model," and "Comprehensive Weapon V3 Model" [1][11][64] - The "Volume Model" is neutral in the short term, while the "Feature Institutional Model" is also neutral. The "Feature Volume Model" indicates bearish signals. The "Smart Algorithm Model" for CSI 300 and CSI 500 shows bearish signals [11][64] - For mid-term A-share market timing, the "Limit-Up and Limit-Down Model," "Up-Down Return Difference Model," and "Calendar Effect Model" are neutral [12][65] - The long-term "Momentum Model" is neutral [13][66] - The "Comprehensive Weapon V3 Model" and "Comprehensive Guozheng 2000 Model" indicate bearish signals for A-shares [14][67] - For Hong Kong stocks, the "Turnover-to-Volatility Model" shows bearish signals, while the "Up-Down Return Difference Model" and "Up-Down Return Similarity Model" are neutral [15][68] - Backtesting results for the "Double Bottom Pattern" show a weekly return of 3.17%, outperforming the Shanghai Composite Index by 4.26%. Since December 31, 2020, the cumulative return is 23.82%, exceeding the Shanghai Composite Index by 11.13% [43][47] - Backtesting results for the "Cup-and-Handle Pattern" show a weekly return of 1.07%, outperforming the Shanghai Composite Index by 2.17%. Since December 31, 2020, the cumulative return is 17.9%, exceeding the Shanghai Composite Index by 5.21% [43][44]

Market Overview - The Hang Seng Index decreased by 1.3% this week, while the Hang Seng Composite Index fell by 1.2%. Small-cap stocks outperformed large-cap and mid-cap stocks, with the Hang Seng Small Cap Index rising by 1.0% [1] - The pharmaceutical sector showed resilience, increasing by 3.8%, while the defense and military industry saw a significant decline of 8.3% [1] Valuation Levels - The valuation of the Hang Seng Index decreased by 1.8% to 10.8x, with the Hang Seng Composite Index also at 10.8x, down by 1.0% [2] - The Hang Seng Biotechnology Index saw a notable increase in valuation by 4.9% to 24.5x, while the Hang Seng High Dividend Index dropped by 3.1% to 7.5x [2] - Among 29 industries, 12 experienced an increase in valuation, with Agriculture and Forestry rising by 12.7% and Consumer Services by 7.5% [2] Earnings Expectations - The EPS for the Hang Seng Index increased by 0.4%, while the Hang Seng Composite Index saw a slight decrease of 0.2% [3] - The ROE Defensive Strategy saw a significant upward revision of 13.9%, while the ROE Offensive Strategy was revised down by 2.8% [3] - A total of 10 industries had upward revisions in EPS, with Comprehensive Finance seeing the largest increase of 36.0%, while 18 industries had downward revisions, with Electronics down by 9.2% [3]

Investment Rating - The report maintains a "Buy" rating for WuXi AppTec (02268.HK) with a target price of HKD 68.47, reflecting a strong long-term growth outlook despite short-term challenges [3][5]. Core Insights - WuXi AppTec is positioned as a global leader in ADC CRDMO, with a solid order backlog and capacity expansion plans. The company is expected to experience robust long-term growth, with adjusted net profit forecasts for 2025-2027 at RMB 14.8 billion, RMB 20.3 billion, and RMB 27.1 billion respectively [3][10]. - The company achieved a revenue of RMB 59.4 billion in 2025, representing a year-on-year growth of 46.7%, with overseas revenue contributing 85% of total sales, indicating a significant increase in international market penetration [10]. - The report highlights the company's strong order intake, with new orders totaling USD 1.33 billion in 2025, a 41% increase year-on-year, and a backlog of USD 1.49 billion, up 50.3% year-on-year, ensuring a solid revenue foundation [10]. Financial Performance Summary - Revenue projections for 2023 to 2027 are as follows: RMB 2,124 million (2023), RMB 4,052 million (2024), RMB 5,944 million (2025), RMB 8,129 million (2026), and RMB 10,844 million (2027), with respective year-on-year growth rates of 114.4%, 90.8%, 46.7%, 36.8%, and 33.4% [4]. - The company's gross profit is expected to reach RMB 21.4 billion in 2025, with a gross margin of 36.0%, reflecting operational efficiency improvements and increased capacity utilization [4][10]. - The net profit attributable to the parent company is projected to be RMB 1.48 billion in 2025, with a net profit margin of 24.9% [4][10].